A 64-year-old female presented to our hospital with a chronic cough. She was diagnosed with cStage ⅢA small cell lung cancer(cT2aN2M0, limited disease). On admission for chemoradiation therapy, laboratory data incidentally revealed liver dysfunction. Further examination resulted in the patient being diagnosed with autoimmune hepatitis. Oral prednisolone therapy was started, and after the improvement of liver function tests, consecutive chemoradiation therapy with cisplatin and etoposide was administered. To the best of our knowledge, this is the first report of a patient with autoimmune hepatitis and small cell lung cancer. Autoimmune hepatitis might arise as a paraneoplastic syndrome.Pancreatic cancer is ranked 4th in Japan in terms of number of deaths so far in 2019, surpassing liver cancer. Unlike other types of cancer, the number of patients in Japan is epidemiologically showing an upward trend, and 70% of cases are unresectable at diagnosis. Therefore, development of chemotherapy that improves the prognosis and maintains and improves the quality of life of the patient is a critical issue. Against this backdrop, the efficacy of nanoliposomal irinotecan(nal-IRI)in combination with fluorouracil and folinic acid(FF)for progressive metastatic pancreatic cancer after previous gemcitabine therapy was confirmed in Europe in 2015 ahead of Japan. In NAPOLI-1, an overseas phase Ⅲ study of this therapy, a significant improvement in overallsurvivalwas shown as compared with patients who received FF alone(median 6.1 months for nal-IRI plus FF vs 4.2 months for FF alone, p=0.012). Therefore, this study yielded important evidence for second-line treatment of pancreatic cancer around the world. In Japan, a phase Ⅱ study was conducted to confirm the efficacy and safety of this therapy, which found a significant prolongation of progression-free survival(as assessed by the investigator)with this therapy as compared with FF alone(median 2.7 months for nal-IRI plus FF vs 1.5 months for FF alone, p=0.039). In the latest version of Clinical Practice Guidelines for Pancreatic Cancer published in Japan in July 2019, nal-IRI plus FF therapy was included in a statement as a treatment option after a gemcitabine-based regimen. This paper provides an overview of development of this new nal-IRI plus FF therapy and relevant information. Drug therapies for pancreatic cancer currently being developed in Japan, as well as the position of this therapy in pancreatic cancer therapy in Japan and what the expectations are in the clinical setting, are also discussed.Appetite loss and weight loss associated with cancer have negative effects on the quality of life and OS of cancer patients. We conducted a web questionnaire survey for healthcare professionals(doctors and medical staff), patients and families to clarify the problem awareness for appetite loss and weight loss associated with cancer. As a result, it turned out that families were more concerned about patients' appetite loss and weight loss, and nearly half of patients haven't consulted their symptoms to healthcare professionals, and it meant that patients missed the opportunity to receive medical intervention due to no consultation. While healthcare professionals have a strong desire to provide dedicated treatment for appetite loss and weight loss in cancer patients, the proportion of patients and families who replied their symptom had improved with the intervention was low. In the near future, it will be necessary to enlighten the importance of symptom management to patients and families and pay attention to their symptom change for healthcare professionals.Colorectal cancer(CRC)accounted for the largest number of new cases of cancer in 2018. CRC is caused by a multifactorial disease process including disruption of the circadian rhythm. Period 1(PER1),as one of the circadian genes,has a role in the cell cycle as well as influence on the cancer process. In this research,we investigate the association of PER1(rs3027188) polymorphism and susceptibility to CRC in conjunction with gender and smoking status. This research was a case-control study in the Japanese population which included 121 CRC patients and 197 noncancerous clinical controls. Genomic deoxyribonucleic acid(DNA)was extracted from peripheral blood lymphocytes. The analysis to detect single-nucleotide polymorphisms( SNPs)in PER1(rs3027188)used polymerase chain reaction-restriction fragment length polymorphism(PCR-RFLP). Overall,there was no significant association between PER1(rs3027188)and CRC. When stratified by gender and smoking status,the results indicated that,compared with the C/C genotype,the G/G genotype among females was significantly less common in the cancer cases than in the controls(adjusted ORs 0.19[95%CI 0.04-0.95]). A significant association was found between the G allele of PER1(rs3027188)and reduced risk of CRC in females,while smoking had no association with PER1(rs3027188)in CRC.Purpose Skin toxicities associated with anti-epidermal growth factor receptor(EGFR)antibodies, have a profound effect on the continuation of treatment. We assessed the efficacy and safety of vitamin K1(VK1)ointment for acneiform eruptions induced by anti-EGFR antibody treatment. Methods The VK1 ointment was applied to one-half of an affected area and placebo ointment was applied to the other half twice a day for 8 weeks, with photography and clinical evaluation being performed every 2 weeks. The primary endpoint was the change of the VK1/placebo ratio for the number of acneiform eruptions counted by an independent dermatologist between the onset and end of the treatment period. Results A total of 30 patients were enrolled.  https://www.selleckchem.com/products/vb124.html  The mean VK1/placebo ratio for the number of acneiform eruptions between the onset and end of the treatment period was -0.158±0.680 and 0.146±0.575, respectively, which was not statistically significant(p=0.069). The mean number of acneiform eruptions at each treatment period at the VK1 and placebo application sites was gradually decreased according to the treatment period. Conclusion VK1 ointment was not effective against acneiform eruptions induced by treatment with cetuximab or panitumumab. Reassessment of the VK1 concentration in the ointment and the endpoint of skin lesions is required before designing further studies.